J&J partners with Intrexon; Acne drug developer Novan raises $30M;

@FierceBiotech: As trouble mounts, a chastened Martin Shkreli says bad boy persona was just an 'experiment.' Article | Follow @FierceBiotech

@JohnCFierce: Orbimed rings up $950M for biotech Fund VI. Report | Follow @JohnCFierce

@DamianFierce: this is a particularly belabored headline. FDA release | Follow @DamianFierce

> Intrexon ($XON) has struck a collaboration pact with Johnson & Johnson ($JNJ), looking to focus on new therapies that prevent at-risk patients from developing diabetes. Release

> Novan Therapeutics has raised more than $30 million in new funding, according to a new SEC filing. The biotech's lead drug is SB204, which is now in late-stage development for acne, with a Phase III expected to launch in Q1 2016. Filing

> Philadelphia-based Immunome raised $5 million, which will be spent developing new therapeutic antibodies to fight cancer. Release

> Johnson & Johnson backed out of a hepatitis C project with partner Medivir ($MVIR) after charting meager efficacy in Phase I. More (PDF)

> Ionis Pharmaceuticals ($IONS), the former Isis Pharmaceuticals, banked $5 million in its ongoing collaboration with Biogen ($BIIB) after advancing an undisclosed preclinical treatment. News

Medical Device News

@FierceMedDev: ICYMI yesterday: UCLA spinout nabs $10M Series A to diagnose, track traumatic brain injury. Report | Follow @FierceMedDev

@EmilyWFierce: Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story from FiercePharmaMarketing | Follow @EmilyWFierce

> Micro-cap liquid biopsy Dx player Biocept nabs $15M financing from Chicago growth investor. Report

> Olympus played down early report of superbug infections linked to duodenoscope devices. Article

Pharma News

@FiercePharma: Shift in law helps local pharma groups in the Philippines. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: WuXi clarifies just what AstraZeneca is buying, or actually what it isn't buying. Report | Follow @EricPFierce

@CarlyHFierce: Valeant's rep-retention plan worked. Now, its sales folks are 'ready and waiting.' FiercePharmaMarketing story | Follow @CarlyHFierce

> GSK's new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says. Article

> German generics maker mulls $1.1B sale amid pharma's M&A frenzy: Reuters. Report

Pharma Manufacturing News

> Sun said to be discussing $2.3B deal for Intas: DealStreetAsia. Item

> GSK recalls nearly 130,000 Ventolin inhalers. More

> Alnylam looks at building $100M plant outside Cambridge. Story

> Novartis selling French Alcon plant to Recipharm. Article

> Sun says the FDA has issued warning letter for Halol plant. Report

Drug Delivery News

> Antibiotic gel can prevent infection in bone implants. Report

> Eli Lilly partners with Halozyme to develop subcutaneous injectables. News

> FDA approves first chewable extended-release tablet, creating new drug delivery partnership opportunity. More

> J&J's Janssen teams up with Intrexon for diabetes pill. Story

> Startup gets $7M in funding to test its toenail fungus-fighting micro-insert. Article

Pharma Asia News

> Shift in law helps local pharma groups in the Philippines. Item

> Sun Pharma said to be in talks to buy Intas for $2.3B. Story

> 2015 was the year of the (most likely Chinese) health hacker: FT. More

> SciClone Pharmaceuticals sets mucositis treatment for China. Item

> Indian M&A deals top $1.5B in 2015 led by overseas acquisitions. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.